Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is a clinical-stage pharmaceutical company that develops cannabinoid treatments for rare psychiatric and neurological conditions. It focuses on patients and conditions that have very few options on the current pharmaceutical market. There’s optimism in this stock today thanks to positive results surrounding the Zygel Phase 2 study. Zygel is a […]
